SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Roudy who wrote ()5/20/1998 12:27:00 AM
From: Bob L  Read Replies (1) of 1762
 
So IDEC pops a press release with data on treatment on intermediate and high grade. biz.yahoo.com. This strikes me as odd, because last time I looked they seemed to be treating low grade, even in the chop and rituxan combo. I'm not sure what to make of this study. Will it be worth it to shell out the extra bucks for rituxan on top of chop to get a slightly higher chance of response?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News